IL312583A - Composition for treatment and prevention of covid-19 - Google Patents
Composition for treatment and prevention of covid-19Info
- Publication number
- IL312583A IL312583A IL312583A IL31258324A IL312583A IL 312583 A IL312583 A IL 312583A IL 312583 A IL312583 A IL 312583A IL 31258324 A IL31258324 A IL 31258324A IL 312583 A IL312583 A IL 312583A
- Authority
- IL
- Israel
- Prior art keywords
- covid
- prevention
- treatment
- composition
- Prior art date
Links
- 208000025721 COVID-19 Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163276410P | 2021-11-05 | 2021-11-05 | |
| PCT/EP2022/080837 WO2023079086A1 (en) | 2021-11-05 | 2022-11-04 | Composition for treatment and prevention of covid-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312583A true IL312583A (en) | 2024-07-01 |
Family
ID=84367072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312583A IL312583A (en) | 2021-11-05 | 2022-11-04 | Composition for treatment and prevention of covid-19 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230242626A1 (en) |
| AU (1) | AU2022383505A1 (en) |
| CA (1) | CA3237462A1 (en) |
| IL (1) | IL312583A (en) |
| TW (1) | TW202342095A (en) |
| WO (1) | WO2023079086A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202342510A (en) | 2022-02-18 | 2023-11-01 | 英商Ｒｑ生物科技有限公司 | Antibodies |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| MX9204374A (en) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION. |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DK1071700T3 (en) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glycosylation modification of antibodies to enhance antibody-dependent cellular cytotoxicity |
| ES2694002T3 (en) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polypeptide comprising an Fc region of variant human IgG1 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ES2568898T3 (en) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedure to control the activity of an immunofunctional molecule |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | Process for producing polypeptide |
| WO2002000879A2 (en) | 2000-06-28 | 2002-01-03 | Glycofi, Inc. | Methods for producing modified glycoproteins |
| EA013563B1 (en) | 2000-10-06 | 2010-06-30 | Киова Хакко Кирин Ко., Лтд. | A transgenic non-human animal, producing antibodies with modified sugar chains, a process for producing antibodies composition and a medicament comprising the antibodies |
| WO2002030954A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Method of purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| DE60143544D1 (en) | 2000-12-12 | 2011-01-05 | Medimmune Llc | MOLECULES WITH LONGER MID-TERM, COMPOSITIONS AND THEIR USE |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| IL160170A0 (en) | 2001-08-03 | 2004-07-25 | Glycart Biotechnology Ag | A host cell engineered to produce a polypeptide having increased cytotoxicity |
| KR101060361B1 (en) | 2002-03-19 | 2011-08-29 | 스티칭 디엔스트 랜드보위쿤디그 온데조에크 | Optimization of Glycan Processing in Plants |
| SG179292A1 (en) | 2003-01-22 | 2012-04-27 | Roche Glycart Ag | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
| MX2007013924A (en) | 2005-05-09 | 2008-01-28 | Glycart Biotechnology Ag | Antigen binding molecules having modified fc regions and altered binding to fc receptors. |
| ES2395842T3 (en) | 2006-01-17 | 2013-02-15 | Synthon Biopharmaceuticals B.V. | Compositions and methods for humanization and optimization of N-glycans in plants |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| CA2693677C (en) | 2007-07-12 | 2018-02-13 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
| EP2391384A4 (en) | 2009-01-29 | 2012-12-26 | Medimmune Llc | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
| BR112012027828A2 (en) * | 2010-05-03 | 2016-08-09 | Genentech Inc | matter composition, article of manufacture and method of reducing the viscosity of a protein containing formulation and preparing an aqueous protein containing formulation |
| CA2828289C (en) | 2011-03-29 | 2020-07-21 | Roche Glycart Ag | Antibody fc variants |
| CR20220545A (en) * | 2020-03-26 | 2023-01-09 | Univ Vanderbilt | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
| WO2022035197A1 (en) * | 2020-08-11 | 2022-02-17 | (주)셀트리온 | Stable pharmaceutical formulation |
-
2022
- 2022-10-28 TW TW111141001A patent/TW202342095A/en unknown
- 2022-11-04 CA CA3237462A patent/CA3237462A1/en active Pending
- 2022-11-04 WO PCT/EP2022/080837 patent/WO2023079086A1/en active Application Filing
- 2022-11-04 AU AU2022383505A patent/AU2022383505A1/en active Pending
- 2022-11-04 US US18/052,840 patent/US20230242626A1/en active Pending
- 2022-11-04 IL IL312583A patent/IL312583A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023079086A1 (en) | 2023-05-11 |
| AU2022383505A1 (en) | 2024-06-06 |
| US20230242626A1 (en) | 2023-08-03 |
| TW202342095A (en) | 2023-11-01 |
| CA3237462A1 (en) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288061A (en) | Compounds and methods for the treatment of covid-19 | |
| IL300067A (en) | Compositions and methods for treatment of cancers | |
| EP4171606A4 (en) | Compositions and methods for the treatment of covid-19 | |
| IL308221A (en) | Compositions and methods for the treatment of depression | |
| GB202005097D0 (en) | Treatment and/or prevention of covid-19 infection | |
| IL286437A (en) | Materials and methods for enhanced treatment and prevention of biofilms | |
| IL312583A (en) | Composition for treatment and prevention of covid-19 | |
| IL289251A (en) | Methods and compositions for treatment of pancreatic cancer | |
| EP4110369A4 (en) | Methods of treatment and related compositions | |
| GB201913122D0 (en) | Compositions and methods for treatment of cholangiocarcinoma | |
| IL309952A (en) | Compositions and methods for treatment of melanoma | |
| IL288415A (en) | Compositions and methods for treatment of hemochromatosis | |
| GB202217355D0 (en) | Methods for the prophylaxis and treatment of Covid and Covid-19 | |
| IL287538A (en) | Compositions and methods for treatment of cancer | |
| EP4190323A4 (en) | Composition for prevention and treatment of myopathy | |
| GB201913121D0 (en) | Compositions and methods for treatment of cholangiocarcinoma | |
| GB201913124D0 (en) | Compositions and methods for treatment of cholangiocarcinoma | |
| GB2607584B (en) | Composition and method of treatment | |
| GB202109624D0 (en) | Composition comprising nutgall extract and fraxin as active ingredient for improvement of cognitive ability and for prevention or treatment of dementia | |
| GB202000248D0 (en) | Compositions and methods of treatment | |
| GB202318443D0 (en) | Compositions and methods of treatment | |
| GB202317378D0 (en) | Composition and methods of treatment | |
| GB202218196D0 (en) | Compositions and methods of treatment | |
| GB202316026D0 (en) | Methods of prevention or treatment | |
| EP4052715A4 (en) | Composition for treatment and/or prevention of tumor |